Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.42 EUR
Change Today -0.018 / -4.14%
Volume 0.0
RV9C On Other Exchanges
Symbol
Exchange
Frankfurt
OTC US
As of 2:37 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

reva medical inc - cdi (RV9C) Snapshot

Open
€0.42
Previous Close
€0.44
Day High
€0.42
Day Low
€0.42
52 Week High
08/31/15 - €0.44
52 Week Low
09/12/14 - €0.04
Market Cap
140.6M
Average Volume 10 Days
125.0
EPS TTM
--
Shares Outstanding
337.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REVA MEDICAL INC - CDI (RV9C)

Related News

No related news articles were found.

reva medical inc - cdi (RV9C) Related Businessweek News

No Related Businessweek News Found

reva medical inc - cdi (RV9C) Details

REVA Medical, Inc., a development stage medical device company, focuses on the commercialization of minimally invasive medical devices for the treatment of coronary artery disease in the human heart. It is developing and testing a bioresorbable stent to treat vascular disease in humans under the Fantom scaffolds name. The company was formerly known as MD3, Inc. and changed its name to REVA Medical, Inc. in March 2002. REVA Medical, Inc. was founded in 1998 and is headquartered in San Diego, California.

53 Employees
Last Reported Date: 08/10/15
Founded in 1998

reva medical inc - cdi (RV9C) Top Compensated Officers

Co-founder, Chairman and Chief Executive Offi...
Total Annual Compensation: $430.5K
President and Chief Operating Officer
Total Annual Compensation: $447.1K
Chief Financial Officer and Company Secretary
Total Annual Compensation: $515.2K
Senior Vice President of Clinical and Regulat...
Total Annual Compensation: $353.7K
Senior Vice President of Product Development
Total Annual Compensation: $348.7K
Compensation as of Fiscal Year 2014.

reva medical inc - cdi (RV9C) Key Developments

REVA Medical, Inc. Appoints Regina Groves as Chief Executive Officer, Effective September 21, 2015

REVA Medical, Inc. announced the appointment of Regina Groves as its Chief Executive Officer, effective September 21, 2015. Ms. Groves will replace Robert Stockman, who will remain as non-executive Chairman of the Board of Directors. Ms. Groves brings more than 30 years' experience in medical devices, executive leadership, and financial management to REVA. Her extensive knowledge and background will position the Company well as it continues its clinical trials and prepares for commercial product launch. Most recently, Ms. Groves served as Vice President and General Manager of the AF Solutions, Cardiac Rhythm and Heart Failure division of Medtronic, a leading global medical technology company.

REVA Medical, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

REVA Medical, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $4,832,000 compared to $5,633,000 a year ago. Net loss and comprehensive loss was $4,833,000 or $0.14 per diluted share compared to net income of $5,854,000 or $0.12 per diluted share a year ago. For the six months, the company reported loss from operations of $12,104,000 compared to $10,486,000 a year ago. Net loss and comprehensive loss was $12,109,000 or $0.36 per basic and diluted share compared to $17,503,000 or $0.52 per basic and diluted share a year ago. Net cash used for operating activities was $10,829,000 compared to $9,437,000 a year ago. Purchases of property and equipment were $338,000 compared to $508,000 a year ago. Loss from ordinary activities, after tax attributable to members was $17,503,000 compared to $12,109,000 a year ago. Net tangible assets per share of common stock were $1.27 compared to loss per share of $0.33 a year ago.

REVA Medical, Inc., Q2 2015 Earnings Call, Aug 12, 2015

REVA Medical, Inc., Q2 2015 Earnings Call, Aug 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RV9C:GR €0.42 EUR -0.018

RV9C Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RV9C.
View Industry Companies
 

Industry Analysis

RV9C

Industry Average

Valuation RV9C Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REVA MEDICAL INC - CDI, please visit www.revamedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.